Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medic...
August 05 2019 - 06:00AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) therapies for cancer, today announced the
appointment of Rafael G. Amado, M.D., as Executive Vice President
of Research and Development and Chief Medical Officer. In this new
position, Dr. Amado will lead Allogene’s clinical and research
functions with the goal of rapidly advancing our pipeline of
allogeneic CAR T therapies for hematologic and solid tumors.
Dr. Amado’s addition to the senior leadership team at
Allogene reunites him with many former colleagues, including Arie
Belldegrun, M.D. FACS, Executive Chairman and Co-Founder, who
previously worked with Dr. Amado at UCLA and David Chang, M.D.,
Ph.D., President, Chief Executive Officer and Co-Founder, who
worked with him at UCLA and Amgen. Dr. Amado is expected to start
with Allogene on or about September 3, 2019.
“I have observed first-hand Rafael’s exceptional ability to lead
and successfully execute the clinical development of innovative
therapies,” said Dr. Chang. “People are the key component of
success. Rafael’s deep expertise in and passion for advancing
breakthrough therapies for patients will be a perfect fit for
Allogene as we continue to advance the development of our AlloCAR T
pipeline.”
Dr. Amado has more than 15 years of biotechnology and
pharmaceutical industry experience leading clinical and research
teams. He joins Allogene from Adaptimmune, where he served as
President of R&D, after serving as Chief Medical Officer. Prior
to Adaptimmune, he held several roles of increasing responsibility
at GSK, most recently as Senior Vice President and Head of Oncology
R&D. In that position, Dr. Amado was responsible for
integrating oncology R&D activities, from drug target
identification to clinical development and registration globally.
He oversaw the development and registration of more than 15 novel
indications across six products and led the development of a
pipeline of products in novel areas of cancer biology. Prior to
GSK, Dr. Amado served as Executive Director of Therapeutic Oncology
at Amgen, where he was responsible for worldwide clinical research
strategy and execution and oversaw development activities for
several investigational agents for molecularly characterized
tumors. Before joining Amgen, he was on the faculty at the
University of California, Los Angeles, most recently serving as
Assistant Clinical Professor, Department of Medicine, Division of
Hematology/Oncology.
“I’ve built a career leading the development of a number of
breakthrough therapies in hematology and oncology, and the last few
years advancing adaptive T-cell therapy. I am excited by the
opportunity to be a part of the team at Allogene as I believe they
truly are poised to lead the next revolution in cancer treatment,”
said Dr. Amado. “It is also personally gratifying to once again
work alongside David Chang and Arie Belldegrun, as well as other
members of the company’s world-class leadership team, and I am
ready to hit the ground running as we build upon pioneering science
that has the potential to transform cancer treatment for patients
worldwide.”
Dr. Amado received an M.D. from the University of Seville School
of Medicine and completed his internship and residency in internal
medicine at Michael Reese Hospital and Medical Center, a University
of Chicago-affiliated hospital. He completed a fellowship in
hematology/oncology at the University of California, Los
Angeles.
About Allogene Therapeutics Allogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the
development of allogeneic chimeric antigen receptor T cell
(AlloCAR T™) therapies for cancer. Led by a world-class management
team with significant experience in cell therapy, Allogene is
developing a pipeline of “off-the-shelf” CAR T cell
therapy candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and
at greater scale to more patients. For more information,
please visit www.allogene.com, and follow @AllogeneTx on
Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The press release may, in some cases, use terms
such as "predicts," "believes," "potential," "proposed,"
"continue," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should" or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Forward-looking statements
include statements regarding intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things: the ability to develop allogeneic CAR T therapies for
cancer and the potential benefits of AlloCAR T therapy. Various
factors may cause differences between Allogene’s expectations and
actual results as discussed in greater detail in Allogene’s filings
with the Securities and Exchange Commission (SEC),
including without limitation in its Form 10-Q for the quarter
ended March 31, 2019. Any forward-looking statements that are
made in this press release speak only as of the date of this press
release. Allogene assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Mar 2023 to Mar 2024